Portola Pharmaceuticals Stock Price, News & Analysis (NASDAQ:PTLA)

$49.28 0.13 (0.26 %)
(As of 11/20/2017 01:42 PM ET)
Previous Close$49.15
Today's Range$48.57 - $49.50
52-Week Range$17.15 - $67.10
Volume336,200 shs
Average Volume986,339 shs
Market Capitalization$3.21559 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.23

About Portola Pharmaceuticals (NASDAQ:PTLA)

Portola Pharmaceuticals logoPortola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company's two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company's Syk is a mediator of immune response in various types of immune cells. The Company has a program of selective Syk inhibitors, one of which is partnered with Ora Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa in development for extended duration venous thromboembolism (VTE) prophylaxis in acute medically ill patients. Andexanet alfa is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:PTLA
  • CUSIP: N/A
  • Web: www.portola.com
Debt:
  • Debt-to-Equity Ratio: 0.24%
  • Current Ratio: 8.31%
  • Quick Ratio: 8.31%
Sales & Book Value:
  • Annual Sales: $35.5 million
  • Price / Sales: 90.58
  • Book Value: $3.41 per share
  • Price / Book: 14.45
Profitability:
  • Trailing EPS: ($4.32)
  • Net Income: ($269,040,000.00)
  • Net Margins: -938.19%
  • Return on Equity: -110.46%
  • Return on Assets: -61.18%
Misc:
  • Employees: 163
  • Outstanding Shares: 65,250,000
 

Frequently Asked Questions for Portola Pharmaceuticals (NASDAQ:PTLA)

What is Portola Pharmaceuticals' stock symbol?

Portola Pharmaceuticals trades on the NASDAQ under the ticker symbol "PTLA."

How were Portola Pharmaceuticals' earnings last quarter?

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) issued its earnings results on Monday, November, 6th. The biopharmaceutical company reported ($1.41) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.49) by $0.08. The biopharmaceutical company had revenue of $3.83 million for the quarter, compared to analysts' expectations of $4.71 million. Portola Pharmaceuticals had a negative return on equity of 110.46% and a negative net margin of 938.19%. Portola Pharmaceuticals's quarterly revenue was down 58.9% compared to the same quarter last year. During the same period last year, the business earned ($1.64) EPS. View Portola Pharmaceuticals' Earnings History.

Where is Portola Pharmaceuticals' stock going? Where will Portola Pharmaceuticals' stock price be in 2017?

8 analysts have issued 12-month target prices for Portola Pharmaceuticals' shares. Their forecasts range from $27.00 to $81.00. On average, they anticipate Portola Pharmaceuticals' share price to reach $67.67 in the next twelve months. View Analyst Ratings for Portola Pharmaceuticals.

What are Wall Street analysts saying about Portola Pharmaceuticals stock?

Here are some recent quotes from research analysts about Portola Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California. " (8/8/2017)
  • 2. Cowen and Company analysts commented, "Portola hosted an investor event at the American College of Cardiology (ACC) annual meeting. Data from betrixaban's APEX Phase III and AndexXa's ANNEXA-4 Phase IV trials were discussed. Investors were keenly focused on examining the APEX clinical data ahead of betrixaban's June PDUFA. While risk remains, we think approval is more likely than not. We remain at Outperform." (3/20/2017)

Who are some of Portola Pharmaceuticals' key competitors?

Who are Portola Pharmaceuticals' key executives?

Portola Pharmaceuticals' management team includes the folowing people:

  • Hollings C. Renton III, IndependentChairman of the Board (Age 70)
  • William Lis, Chief Executive Officer, Director (Age 52)
  • Mardi C. Dier, Chief Financial Officer, Executive Vice President (Age 53)
  • John T. Curnutte M.D. Ph.D., Executive Vice President - Research & Development (Age 65)
  • Tao Fu, Executive Vice President, Chief Commercial and Business officer (Age 45)
  • Jeffrey W. Bird M.D. Ph.D., Independent Director (Age 56)
  • Laura A. Brege, Independent Director (Age 59)
  • Dennis M. Fenton Ph.D., Independent Director (Age 65)
  • Charles J. Homcy M.D., Independent Director (Age 68)
  • John H. Johnson, Independent Director (Age 59)

Who owns Portola Pharmaceuticals stock?

Portola Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (1.29%), Kornitzer Capital Management Inc. KS (1.13%), Zevenbergen Capital Investments LLC (1.00%), Sectoral Asset Management Inc (0.78%), Pinnacle Associates Ltd. (0.75%) and Pictet Asset Management Ltd. (0.83%). Company insiders that own Portola Pharmaceuticals stock include (Mauritius) Pte Ltd Maxwell, Charles J Homcy, Fullerton Management Pte Ltd, Jeffrey W Bird, John T Curnutte, Mardi Dier, Tao Fu and William Lis. View Institutional Ownership Trends for Portola Pharmaceuticals.

Who sold Portola Pharmaceuticals stock? Who is selling Portola Pharmaceuticals stock?

Portola Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., OxFORD Asset Management LLP, EAM Investors LLC, First Trust Advisors LP, Nicholas Investment Partners LP, Marcus Capital LLC, Hanseatic Management Services Inc. and New York State Common Retirement Fund. Company insiders that have sold Portola Pharmaceuticals company stock in the last year include (Mauritius) Pte Ltd Maxwell, Charles J Homcy, John T Curnutte, Mardi Dier, Tao Fu and William Lis. View Insider Buying and Selling for Portola Pharmaceuticals.

Who bought Portola Pharmaceuticals stock? Who is buying Portola Pharmaceuticals stock?

Portola Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS, Zevenbergen Capital Investments LLC, Sphera Funds Management LTD., Sectoral Asset Management Inc, Bank of New York Mellon Corp, Schwab Charles Investment Management Inc., Chicago Equity Partners LLC and Prudential Financial Inc.. Company insiders that have bought Portola Pharmaceuticals stock in the last two years include Fullerton Management Pte Ltd and Jeffrey W Bird. View Insider Buying and Selling for Portola Pharmaceuticals.

How do I buy Portola Pharmaceuticals stock?

Shares of Portola Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Portola Pharmaceuticals' stock price today?

One share of Portola Pharmaceuticals stock can currently be purchased for approximately $49.28.

How big of a company is Portola Pharmaceuticals?

Portola Pharmaceuticals has a market capitalization of $3.21559 billion and generates $35.5 million in revenue each year. The biopharmaceutical company earns ($269,040,000.00) in net income (profit) each year or ($4.32) on an earnings per share basis. Portola Pharmaceuticals employs 163 workers across the globe.

How can I contact Portola Pharmaceuticals?

Portola Pharmaceuticals' mailing address is 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-246-7000 or via email at [email protected]


MarketBeat Community Rating for Portola Pharmaceuticals (NASDAQ PTLA)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  240 (Vote Outperform)
Underperform Votes:  135 (Vote Underperform)
Total Votes:  375
MarketBeat's community ratings are surveys of what our community members think about Portola Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Portola Pharmaceuticals (NASDAQ:PTLA)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 7 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $67.67 (37.31% upside)

Consensus Price Target History for Portola Pharmaceuticals (NASDAQ:PTLA)

Price Target History for Portola Pharmaceuticals (NASDAQ:PTLA)

Analysts' Ratings History for Portola Pharmaceuticals (NASDAQ:PTLA)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/7/2017Oppenheimer Holdings, Inc.Reiterated RatingBuy$80.00N/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingOverweight$75.00 -> $81.00N/AView Rating Details
8/23/2017Credit Suisse GroupUpgradeNeutral -> Outperform$70.00HighView Rating Details
6/26/2017Cowen and CompanyBoost Price TargetOutperform$45.00 -> $70.00HighView Rating Details
6/26/2017William BlairReiterated RatingOutperformHighView Rating Details
6/26/2017Citigroup Inc.Boost Price TargetBuy$51.00 -> $78.00MediumView Rating Details
2/24/2017CIBCUpgradeMarket Perform -> OutperformN/AView Rating Details
1/11/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$22.00 -> $27.00N/AView Rating Details
(Data available from 11/20/2015 forward)

Earnings

Earnings History and Estimates Chart for Portola Pharmaceuticals (NASDAQ:PTLA)

Earnings by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)

Earnings History by Quarter for Portola Pharmaceuticals (NASDAQ PTLA)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017Q3 2017($1.49)($1.41)$4.71 million$3.83 millionViewN/AView Earnings Details
8/9/2017Q2 2017($1.10)($1.22)$4.28 million$3.79 millionViewListenView Earnings Details
5/8/2017Q1 2017($1.20)($0.74)$4.21 million$5.12 millionViewListenView Earnings Details
2/28/2017Q4 2016($1.12)($0.95)$3.98 million$13.70 millionViewListenView Earnings Details
11/7/2016Q3($1.10)($1.64)$4.10 million$9.30 millionViewListenView Earnings Details
8/9/2016Q216($1.20)($1.02)$4.38 million$4.23 millionViewListenView Earnings Details
5/5/2016Q1($1.06)($1.15)$7.91 million$8.30 millionViewListenView Earnings Details
2/26/2016Q415($1.12)($1.23)$2.43 million$4.40 millionViewListenView Earnings Details
8/4/2015Q215($1.07)($1.12)$2.30 million$2.39 millionViewListenView Earnings Details
5/6/2015Q115($1.09)($0.95)$2.60 million$2.36 millionViewListenView Earnings Details
3/2/2015Q414($0.90)($0.82)$2.40 million$2.41 millionViewListenView Earnings Details
11/10/2014Q314($0.92)($0.86)$2.73 million$2.40 millionViewListenView Earnings Details
8/6/2014Q214($0.79)($0.76)$2.44 million$2.42 billionViewListenView Earnings Details
5/12/2014Q114($0.72)($0.75)$1.81 million$2.40 millionViewListenView Earnings Details
2/27/2014Q4($0.57)($0.63)$2.17 million$2.10 millionViewListenView Earnings Details
8/15/2013($0.72)($1.47)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Portola Pharmaceuticals (NASDAQ:PTLA)
2017 EPS Consensus Estimate: ($5.52)
2018 EPS Consensus Estimate: ($2.69)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($1.30)($1.12)($1.21)
Q2 20172($1.24)($1.06)($1.15)
Q3 20172($1.68)($1.45)($1.57)
Q4 20172($1.67)($1.52)($1.60)
Q1 20181($1.04)($1.04)($1.04)
Q2 20181($0.85)($0.85)($0.85)
Q3 20181($0.57)($0.57)($0.57)
Q4 20181($0.23)($0.23)($0.23)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Portola Pharmaceuticals (NASDAQ:PTLA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Portola Pharmaceuticals (NASDAQ PTLA)

Insider Ownership Percentage: 4.90%
Institutional Ownership Percentage: 82.36%
Insider Trades by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)
Institutional Ownership by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)

Insider Trades by Quarter for Portola Pharmaceuticals (NASDAQ PTLA)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/18/2017John T. CurnutteInsiderSell10,000$65.00$650,000.00View SEC Filing  
7/18/2017Tao FuEVPSell5,812$65.00$377,780.00View SEC Filing  
7/11/2017Mardi DierVPSell23,350$60.00$1,401,000.00View SEC Filing  
6/28/2017William LisCEOSell269,299$55.43$14,927,243.57View SEC Filing  
6/27/2017Mardi DierVPSell93,392$55.46$5,179,520.32View SEC Filing  
6/26/2017John T. CurnutteInsiderSell60,000$57.88$3,472,800.00View SEC Filing  
6/26/2017Tao FuEVPSell7,000$57.14$399,980.00View SEC Filing  
6/23/2017Charles J. HomcyDirectorSell120,803$53.06$6,409,807.18View SEC Filing  
6/1/2017(Mauritius) Pte Ltd MaxwellMajor ShareholderSell1,700,000$34.40$58,480,000.00View SEC Filing  
6/1/2017Jeffrey W BirdDirectorBuy119,442$31.85$3,804,227.70View SEC Filing  
4/11/2017William LisCEOSell6,750$36.06$243,405.00View SEC Filing  
4/10/2017Tao FuEVPSell1,097$36.97$40,556.09View SEC Filing  
3/15/2017Charles J. HomcyDirectorSell50,000$40.06$2,003,000.00View SEC Filing  
3/15/2017Mardi DierVPSell10,235$40.02$409,604.70View SEC Filing  
5/2/2016William LisCEOSell5,675$23.86$135,405.50View SEC Filing  
12/9/2015Fullerton Management Pte LtdMajor ShareholderBuy750,000$48.00$36,000,000.00View SEC Filing  
9/18/2015Charles J. HomcyDirectorSell40,067$56.25$2,253,768.75View SEC Filing  
9/18/2015Mardi DierCFOSell8,912$55.00$490,160.00View SEC Filing  
7/15/2015John T CurnutteEVPSell10,000$50.00$500,000.00View SEC Filing  
7/15/2015William LisCEOSell50,000$50.00$2,500,000.00View SEC Filing  
7/13/2015Charles J HomcyDirectorSell50,000$48.00$2,400,000.00View SEC Filing  
7/2/2015William LisCEOSell15,000$45.60$684,000.00View SEC Filing  
7/1/2015William LisCEOSell30,000$45.01$1,350,300.00View SEC Filing  
6/30/2015William LisCEOSell15,000$44.48$667,200.00View SEC Filing  
6/29/2015Charles J HomcyDirectorSell100,000$43.78$4,378,000.00View SEC Filing  
6/22/2015John T CurnutteEVPSell10,000$47.50$475,000.00View SEC Filing  
6/16/2015John T CurnutteEVPSell10,000$45.00$450,000.00View SEC Filing  
6/8/2015Mardi DierCFOSell16,119$43.00$693,117.00View SEC Filing  
5/29/2015John T CurnutteEVPSell10,000$42.50$425,000.00View SEC Filing  
5/28/2015John T CurnutteEVPSell10,000$40.30$403,000.00View SEC Filing  
5/27/2015Mardi DierCFOSell6,076$41.00$249,116.00View SEC Filing  
5/12/2015Mardi DierCFOSell13,290$37.88$503,425.20View SEC Filing  
5/11/2015Hollings RentonDirectorSell10,520$38.33$403,231.60View SEC Filing  
5/11/2015Mardi DierCFOSell13,674$38.21$522,483.54View SEC Filing  
4/30/2015William LisCEOSell45,000$35.60$1,602,000.00View SEC Filing  
2/23/2015Charles J HomcyDirectorSell20,000$40.00$800,000.00View SEC Filing  
2/23/2015John T CurnutteEVPSell10,000$40.00$400,000.00View SEC Filing  
2/23/2015Mardi DierCFOSell5,692$39.95$227,395.40View SEC Filing  
2/18/2015John T CurnutteEVPSell10,000$37.50$375,000.00View SEC Filing  
2/17/2015Charles J HomcyDirectorSell20,000$36.00$720,000.00View SEC Filing  
2/17/2015John T CurnutteEVPSell10,000$35.00$350,000.00View SEC Filing  
2/13/2015Charles J HomcyDirectorSell20,000$34.05$681,000.00View SEC Filing  
2/13/2015John T CurnutteEVPSell10,000$32.50$325,000.00View SEC Filing  
1/28/2015Charles J HomcyDirectorSell19,700$30.00$591,000.00View SEC Filing  
1/20/2015William LisCEOSell20,000$27.32$546,400.00View SEC Filing  
1/16/2015William LisCEOSell20,000$26.94$538,800.00View SEC Filing  
11/25/2014Mardi DierCFOSell1,118$28.23$31,561.14View SEC Filing  
11/20/2014William LisCEOSell40,000$26.95$1,078,000.00View SEC Filing  
11/17/2014William LisCEOSell30,000$26.69$800,700.00View SEC Filing  
10/8/2014(Mauritius) Pte Ltd MaxwellMajor ShareholderBuy1,600,000$26.00$41,600,000.00View SEC Filing  
8/25/2014Mardi DierCFOSell5,000$26.26$131,300.00View SEC Filing  
7/25/2014Mardi DierCFOSell5,000$24.11$120,550.00View SEC Filing  
7/3/2014William LisCEOSell30,000$30.41$912,300.00View SEC Filing  
6/30/2014William LisCEOSell10,000$29.23$292,300.00View SEC Filing  
6/25/2014Mardi DierCFOSell5,000$28.52$142,600.00View SEC Filing  
6/18/2014John T CurnutteEVPSell30,000$28.33$849,900.00View SEC Filing  
6/18/2014Mardi DierCFOSell3,706$29.95$110,994.70View SEC Filing  
6/16/2014John T CurnutteEVPSell10,000$26.00$260,000.00View SEC Filing  
6/10/2014Nicholas GalakatosDirectorSell1,369$23.36$31,979.84View SEC Filing  
5/29/2014Mardi DierCFOSell5,000$23.00$115,000.00View SEC Filing  
5/27/2014William LisCEOSell30,000$20.83$624,900.00View SEC Filing  
5/21/2014William LisCEOSell10,000$19.87$198,700.00View SEC Filing  
5/16/2014Jean Jacques BienaimeDirectorSell1,000$22.03$22,030.00View SEC Filing  
4/25/2014Mardi DierCFOSell5,000$24.14$120,700.00View SEC Filing  
3/25/2014Mardi DierCFOSell5,000$25.69$128,450.00View SEC Filing  
10/22/2013Charles J HomcyDirectorSell95,962$23.75$2,279,097.50View SEC Filing  
5/28/2013(Mauritius) Pte Ltd MaxwellMajor ShareholderBuy700,000$14.50$10,150,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Portola Pharmaceuticals (NASDAQ PTLA)

Source:
DateHeadline
Portola Pharmaceuticals, Inc. (PTLA) Receives Consensus Rating of "Buy" from AnalystsPortola Pharmaceuticals, Inc. (PTLA) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - November 13 at 10:06 PM
Portola Pharmaceuticals, Inc. (PTLA) Expected to Post Quarterly Sales of $2.42 MillionPortola Pharmaceuticals, Inc. (PTLA) Expected to Post Quarterly Sales of $2.42 Million
www.americanbankingnews.com - November 11 at 2:10 AM
Portola Pharmaceuticals, Inc. (PTLA) Expected to Announce Earnings of -$1.60 Per SharePortola Pharmaceuticals, Inc. (PTLA) Expected to Announce Earnings of -$1.60 Per Share
www.americanbankingnews.com - November 9 at 11:04 PM
Portola Pharmaceuticals: A Low-Quality Stock Or Simply Misunderstood?Portola Pharmaceuticals: A Low-Quality Stock Or Simply Misunderstood?
seekingalpha.com - November 9 at 11:57 AM
Portola Pharmaceuticals, Inc. to Post FY2017 Earnings of ($5.07) Per Share, Oppenheimer Holdings Forecasts (PTLA)Portola Pharmaceuticals, Inc. to Post FY2017 Earnings of ($5.07) Per Share, Oppenheimer Holdings Forecasts (PTLA)
www.americanbankingnews.com - November 9 at 7:21 AM
FY2017 EPS Estimates for Portola Pharmaceuticals, Inc. (PTLA) Decreased by William BlairFY2017 EPS Estimates for Portola Pharmaceuticals, Inc. (PTLA) Decreased by William Blair
www.americanbankingnews.com - November 9 at 7:21 AM
Oppenheimer Holdings Equities Analysts Decrease Earnings Estimates for Portola Pharmaceuticals, Inc. (PTLA)Oppenheimer Holdings Equities Analysts Decrease Earnings Estimates for Portola Pharmaceuticals, Inc. (PTLA)
www.americanbankingnews.com - November 8 at 10:44 PM
Portola Pharmaceuticals, Inc. (PTLA) Expected to Earn FY2019 Earnings of $1.11 Per SharePortola Pharmaceuticals, Inc. (PTLA) Expected to Earn FY2019 Earnings of $1.11 Per Share
www.americanbankingnews.com - November 8 at 9:52 PM
Portola Pharmaceuticals Announces New APEX Study Sub-Analyses Data on Betrixaban to be Presented at the ... - NasdaqPortola Pharmaceuticals Announces New APEX Study Sub-Analyses Data on Betrixaban to be Presented at the ... - Nasdaq
www.nasdaq.com - November 7 at 9:10 AM
Portola Pharmaceuticals (PTLA) CEO William Lis on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaPortola Pharmaceuticals' (PTLA) CEO William Lis on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 7 at 9:10 AM
Portola Pharmaceuticals, Inc. to Host Earnings CallPortola Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 7 at 9:10 AM
Portola Pharmaceuticals Appoints Industry Veteran John H. Lawrence, M.D., as Senior Vice President of Product Development and Chief Medical OfficerPortola Pharmaceuticals Appoints Industry Veteran John H. Lawrence, M.D., as Senior Vice President of Product Development and Chief Medical Officer
finance.yahoo.com - November 7 at 9:10 AM
Portola Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate UpdatePortola Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - November 7 at 9:10 AM
Portola Pharmaceuticals posts 3Q lossPortola Pharmaceuticals posts 3Q loss
finance.yahoo.com - November 7 at 9:10 AM
Edited Transcript of PTLA earnings conference call or presentation 6-Nov-17 9:30pm GMTEdited Transcript of PTLA earnings conference call or presentation 6-Nov-17 9:30pm GMT
finance.yahoo.com - November 7 at 9:10 AM
Portola Pharmaceuticals Announces New APEX Study Sub-Analyses Data on Betrixaban to be Presented at the America Heart Association (AHA) Scientific Sessions 2017Portola Pharmaceuticals Announces New APEX Study Sub-Analyses Data on Betrixaban to be Presented at the America Heart Association (AHA) Scientific Sessions 2017
finance.yahoo.com - November 7 at 9:10 AM
Portola Pharmaceuticals, Inc. (PTLA) Announces Quarterly  Earnings Results, Beats Estimates By $0.08 EPSPortola Pharmaceuticals, Inc. (PTLA) Announces Quarterly Earnings Results, Beats Estimates By $0.08 EPS
www.americanbankingnews.com - November 6 at 9:24 PM
Portola Pharmaceuticals to Present at the Credit Suisse 26th Annual Healthcare Conference - GlobeNewswire (press release)Portola Pharmaceuticals to Present at the Credit Suisse 26th Annual Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - November 4 at 9:23 AM
Portola Pharmaceuticals to Present at the Credit Suisse 26th Annual Healthcare ConferencePortola Pharmaceuticals to Present at the Credit Suisse 26th Annual Healthcare Conference
finance.yahoo.com - November 4 at 9:23 AM
Portola Pharmaceuticals to Announce Third Quarter 2017 Financial Results and Host Conference Call on Monday ... - GlobeNewswire (press release)Portola Pharmaceuticals to Announce Third Quarter 2017 Financial Results and Host Conference Call on Monday ... - GlobeNewswire (press release)
globenewswire.com - October 31 at 8:16 AM
Portola Pharmaceuticals, Inc. (PTLA) Scheduled to Post Quarterly Earnings on MondayPortola Pharmaceuticals, Inc. (PTLA) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - October 30 at 9:54 AM
Commit To Purchase Portola Pharmaceuticals At $40, Earn 17.2% Annualized Using Options - NasdaqCommit To Purchase Portola Pharmaceuticals At $40, Earn 17.2% Annualized Using Options - Nasdaq
www.nasdaq.com - October 27 at 11:56 AM
 Brokerages Expect Portola Pharmaceuticals, Inc. (PTLA) Will Post Quarterly Sales of $2.42 Million Brokerages Expect Portola Pharmaceuticals, Inc. (PTLA) Will Post Quarterly Sales of $2.42 Million
www.americanbankingnews.com - October 23 at 11:54 AM
Portola Pharmaceuticals, Inc. (PTLA) Receives Average Recommendation of "Buy" from BrokeragesPortola Pharmaceuticals, Inc. (PTLA) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - October 19 at 6:50 PM
Portola Pharmaceuticals, Inc. Forecasted to Earn FY2017 Earnings of ($4.86) Per Share (PTLA)Portola Pharmaceuticals, Inc. Forecasted to Earn FY2017 Earnings of ($4.86) Per Share (PTLA)
www.americanbankingnews.com - October 13 at 7:54 AM
Portola Pharmaceuticals Supports 2017 World Thrombosis Day Campaign to Raise Awareness about the Persistent ... - GlobeNewswire (press release)Portola Pharmaceuticals Supports 2017 World Thrombosis Day Campaign to Raise Awareness about the Persistent ... - GlobeNewswire (press release)
globenewswire.com - October 12 at 8:38 AM
Portola Pharmaceuticals Supports 2017 World Thrombosis Day Campaign to Raise Awareness about the Persistent ... - GlobeNewswire (press release)Portola Pharmaceuticals Supports 2017 World Thrombosis Day Campaign to Raise Awareness about the Persistent ... - GlobeNewswire (press release)
globenewswire.com - October 12 at 8:38 AM
Portola Pharmaceuticals Supports 2017 World Thrombosis Day Campaign to Raise Awareness about the Persistent Risk of Blood ClotsPortola Pharmaceuticals Supports 2017 World Thrombosis Day Campaign to Raise Awareness about the Persistent Risk of Blood Clots
finance.yahoo.com - October 12 at 8:38 AM
Portola Pharmaceuticals Supports 2017 World Thrombosis Day Campaign to Raise Awareness about the Persistent Risk of Blood ClotsPortola Pharmaceuticals Supports 2017 World Thrombosis Day Campaign to Raise Awareness about the Persistent Risk of Blood Clots
finance.yahoo.com - October 12 at 8:38 AM
Reviewing Portola Pharmaceuticals (PTLA) and Its RivalsReviewing Portola Pharmaceuticals (PTLA) and Its Rivals
www.americanbankingnews.com - October 10 at 9:06 AM
Portola Pharmaceuticals, Inc. (PTLA) PT Set at $80.00 by Oppenheimer Holdings, Inc.Portola Pharmaceuticals, Inc. (PTLA) PT Set at $80.00 by Oppenheimer Holdings, Inc.
www.americanbankingnews.com - October 6 at 9:08 PM
Portola Pharmaceuticals, Inc. (PTLA) Price Target Raised to $81.00Portola Pharmaceuticals, Inc. (PTLA) Price Target Raised to $81.00
www.americanbankingnews.com - October 6 at 11:02 AM
FY2017 EPS Estimates for Portola Pharmaceuticals, Inc. (PTLA) Lifted by AnalystFY2017 EPS Estimates for Portola Pharmaceuticals, Inc. (PTLA) Lifted by Analyst
www.americanbankingnews.com - October 6 at 7:58 AM
$2.42 Million in Sales Expected for Portola Pharmaceuticals, Inc. (PTLA) This Quarter$2.42 Million in Sales Expected for Portola Pharmaceuticals, Inc. (PTLA) This Quarter
www.americanbankingnews.com - October 4 at 3:18 PM
 Brokerages Anticipate Portola Pharmaceuticals, Inc. (PTLA) to Announce -$1.51 EPS Brokerages Anticipate Portola Pharmaceuticals, Inc. (PTLA) to Announce -$1.51 EPS
www.americanbankingnews.com - October 2 at 12:22 PM
Jim Cramer Advises His Viewers On Southwest Airlines And General Electric - BenzingaJim Cramer Advises His Viewers On Southwest Airlines And General Electric - Benzinga
www.benzinga.com - September 27 at 8:21 AM
Cramer's lightning round: Portola's no one-trick ponyCramer's lightning round: Portola's no one-trick pony
finance.yahoo.com - September 27 at 8:20 AM
Technical Reports on Biotech Equities -- Opko Health, Otonomy, Pacific Biosciences of California, and Portola Pharma - PR Newswire (press release)Technical Reports on Biotech Equities -- Opko Health, Otonomy, Pacific Biosciences of California, and Portola Pharma - PR Newswire (press release)
www.prnewswire.com - September 25 at 9:40 AM
Portola Pharmaceuticals, Inc. (PTLA) Given Consensus Recommendation of "Buy" by AnalystsPortola Pharmaceuticals, Inc. (PTLA) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - September 24 at 6:42 PM
Portola - A High-Risk, High-Return Investment Opportunity - Seeking AlphaPortola - A High-Risk, High-Return Investment Opportunity - Seeking Alpha
seekingalpha.com - September 23 at 5:53 AM
Expect A Slow Bleed With Portola PharmaExpect A Slow Bleed With Portola Pharma
seekingalpha.com - September 22 at 7:46 PM
Research Analysts Set Expectations for Portola Pharmaceuticals, Inc.s Q3 2017 Earnings (PTLA)Research Analysts Set Expectations for Portola Pharmaceuticals, Inc.'s Q3 2017 Earnings (PTLA)
www.americanbankingnews.com - September 22 at 6:36 AM
William Blair Weighs in on Portola Pharmaceuticals, Inc.s FY2020 Earnings (PTLA)William Blair Weighs in on Portola Pharmaceuticals, Inc.'s FY2020 Earnings (PTLA)
www.americanbankingnews.com - September 21 at 3:56 PM
Portola Pharma (PTLA) Weakness Tied to Earlier Article in STAT - StreetInsider.comPortola Pharma (PTLA) Weakness Tied to Earlier Article in STAT - StreetInsider.com
www.streetinsider.com - September 20 at 8:02 AM
Todays Research Reports on Trending Tickers: Portola Pharmaceuticals and Synchronoss TechnologiesToday's Research Reports on Trending Tickers: Portola Pharmaceuticals and Synchronoss Technologies
finance.yahoo.com - September 20 at 8:02 AM
 Brokerages Expect Portola Pharmaceuticals, Inc. (PTLA) Will Announce Quarterly Sales of $2.42 Million Brokerages Expect Portola Pharmaceuticals, Inc. (PTLA) Will Announce Quarterly Sales of $2.42 Million
www.americanbankingnews.com - September 15 at 5:20 AM
Portola Shares Lower After Pricing Stock Offering - Biotech MoversPortola Shares Lower After Pricing Stock Offering - Biotech Movers
finance.yahoo.com - September 14 at 9:31 AM
Portola Announces Pricing of Public Offering of Common StockPortola Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - September 13 at 8:01 AM
Portola Pharmaceuticals Inc. (PTLA) Is Falling After Offering AnnouncementPortola Pharmaceuticals Inc. (PTLA) Is Falling After Offering Announcement
www.rttnews.com - September 12 at 8:54 AM
Portola Pharmaceuticals Announces Proposed Offering of Common StockPortola Pharmaceuticals Announces Proposed Offering of Common Stock
finance.yahoo.com - September 12 at 8:54 AM

Social Media

Financials

Chart

Portola Pharmaceuticals (NASDAQ PTLA) Chart for Monday, November, 20, 2017
Loading chart…

This page was last updated on 11/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.